These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 29335156)

  • 1. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
    Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
    Kim JJ; Burger EA; Sy S; Campos NG
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
    Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
    Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
    J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying a Single Optimal Integrated Cervical Cancer Prevention Policy in Norway: A Cost-Effectiveness Analysis.
    Portnoy A; Pedersen K; Nygård M; Trogstad L; Kim JJ; Burger EA
    Med Decis Making; 2022 Aug; 42(6):795-807. PubMed ID: 35255741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
    Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
    Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
    Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
    Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.
    Naber SK; Matthijsse SM; Rozemeijer K; Penning C; de Kok IM; van Ballegooijen M
    PLoS One; 2016; 11(1):e0145548. PubMed ID: 26824771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
    Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
    BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
    Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
    Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
    Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
    Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
    Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
    BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
    Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
    Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.